Eli Lilly News

Morgan Stanley's price objective would suggest a potential downside of 1.12% from the stock's previous close.

JARDIANCE is not for people with type 1 diabetes or for people with diabetic ketoacidosis .

Federal regulators have approved a new treatment from U.S. drugmaker Eli Lilly and Co.

Eli Lilly is locked in a battle over the release of hundreds of thousands of pages of internal documents with two of its former scientists, who were charged earlier this year with wire fraud for allegedly leaking proprietary information about experimental drugs and providing the data to a Chinese drug maker.

MarketResearchreports.biz presents this most up-to-date research on Global and China Insulin Market - Industry Analysis, Size, Share, Growth, Trends and Forecast , 2013 - 2019: Market Size, Trends, and Forecasts Research Report.

Eli Lilly and major shareholder Lilly Endowment Inc sold 250,000 shares of Eli Lilly and stock in a transaction dated Tuesday, July 29th.

Acorda Therapeutics Inc. v. Actavis Laboratories FL Inc. 1:14-cv-00882; filed July 7, 2014 in the District Court of Delaware Infringement of U.S. Patent Nos.

With more than 90 shots on goal and several revenue driving opportunities in 2014 alone, investors should watch it very closely.

Lilly fighting subpoena seeking internal documents Former Lilly scientists seeking info in their defense against charges they leaked company secrets Check out this story on IndyStar.com: http://indy.st/1mZ9QKw Eli Lilly and Co.

Accelerator Corporation Secures $51.1 Million to Support Emerging Biotechnology Research Opportunities in New York City and Seattle Accelerator IV to Bridge Funding Gap for Early Research;Includes New Strategic Investors Eli Lilly and Company, Harris & Harris Group, Inc., Johnson & Johnson Development Corporation, The Partnership Fund for New York ... (more)

The East Side towers of the Alexandria Center for Life Science have attracted giant pharmaceutical companies such as Pfizer Inc. and Eli Lilly & Co.

UC San Diego raised almost $1.1 billion for research over the past year, maintaining the school's standing as one of the nation's 10 largest centers for science, engineering and medicine.

Based on comparable valuations for the industry, the stock is considerably undervalued.

's stock had its "neutral" rating restated by Zacks in a report released on Friday.

Pass this article on to your neighbors, your community members and leaders and to the people in Lockhart's district, many of them in Indianapolis.

Eli Lilly and Co. on Thursday reported profit that declined by 39 percent in its second quarter, and beat analysts' expectations.

Ladies and gentlemen, thank you for standing by. Welcome to the Q 2014 earnings call.

While city officials are supportive of drawing roughly 360 acres of the Covance campus into city limits, it's still unclear how tax breaks on the deal would work.

Second-quarter 2014 revenue declined 17 percent driven by the impact of U.S. patent expirations for Cymbalta and Evista, partially offset by volume growth in several other products.

The loss of Patents over the years, has been the main cause of lower earnings at Eli Lilly and Co , the CEO of the company, Dr. John Lechleiter, said in an interview on CNBC .